Atlas Trials

The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

Clinical trial NCT05494307 · UNKNOWN

Trial details

NCT number
NCT05494307
Sponsor
Peking University People's Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2022-09-01
Primary completion
2023-09-01
Enrollment
228

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.